Study identifies new disease-inducing mechanism for inflammatory bowel disease
Combined, Crohn’s disease and ulcerative colitis affect over 500,000 people in the UK
Read Moreby Jen Brogan | Aug 15, 2024 | News | 0
Combined, Crohn’s disease and ulcerative colitis affect over 500,000 people in the UK
Read Moreby Jen Brogan | Aug 12, 2024 | News | 0
A second dose of the vaccine lowered the incidence of conditions such as heart attack or stroke
Read Moreby Jen Brogan | Jul 31, 2024 | News | 0
Quantum-based technologies will explore infectious diseases, cancer and dementia
Read Moreby Jen Brogan | Jul 30, 2024 | News | 0
The findings could support investigations into human genetics and various complex diseases
Read Moreby Jen Brogan | Jul 5, 2024 | News | 0
Pneumococcus is the leading cause of pneumonia, meningitis and sepsis worldwide
Read Moreby Jen Brogan | Jul 2, 2024 | News | 0
Affecting around 3,755 young people in the UK every year, leukaemia is the most commonly diagnosed cancer in children
Read Moreby Jen Brogan | Jun 20, 2024 | News | 0
The lifelong inflammatory bowel disease affects around one in every 350 people in the UK
Read Moreby Jen Brogan | May 28, 2024 | News | 0
The MRC BRC and the MDU will use the funding and cutting-edge research to improve public health until March 2029
Read Moreby Jen Brogan | May 3, 2024 | News | 0
Neurological disorders, such as epilepsy or chronic pain, affect over three billion people worldwide
Read Moreby Jen Brogan | May 1, 2024 | News | 0
The progressive neurological condition affects more than six million people worldwide
Read Moreby Jen Brogan | Apr 30, 2024 | News | 0
GPT-4 is trained on datasets to offer eye-related advice, diagnosis and management suggestions
Read Moreby Jen Brogan | Apr 18, 2024 | News | 0
Breast cancer was responsible for 2.3 million diagnoses and 670,000 deaths globally in 2022
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479